Allarity Therapeutics Confirms Expanded Eligibility For Ongoing Phase 2 Trial In Advanced Ovarian Cancer
Benzinga Newsdesk 10 hours ago
News
Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observationsAdds platinum-refractory patients as well as those with hard-to-measure but clinically evaluable
Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations
Adds platinum-refractory patients as well as those with hard-to-measure but clinically evaluable disease
Leverages existing clinical sites to evaluate groups independently and accelerate potential paths to commercialization
TARPON SPRINGS, Fla., November 16, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today confirmed expanded eligibility for its ongoing Phase 2 trial in advanced ovarian cancer. This opens the study to patients with primary platinum-refractory disease and patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors ("RECIST").
The expansion into additional patient populations was prompted by the enthusiasm of clinical investigators for the potential of stenoparib as a well-tolerated, oral treatment option for advanced ovarian cancer patients and reflects the encouraging early performance of the ongoing trial in platinum-resistant and platinum-ineligible patients. Importantly, the addition of these new patients now allows Allarity to build upon prior evidence of remarkable, durable clinical benefit in primary platinum-refractory disease while also evaluating stenoparib's potential role across a broader spectrum of advanced ovarian cancer patients.
